RARITAN, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) (“Ortho” or the “Company”), one of the world’s largest pure-play in vitro diagnostics (IVD) ...

Raritan’s Ortho Clinical Diagnostics Holdings plc and Quidel Corp., based in San Diego, on Dec. 23 announced entering a definitive agreement that will see Quidel acquire Ortho in a deal valued at ...

-- Ortho's new VITROS(R) Anti-SARS-CoV-2 Total N test detects the individual's immune response to the COVID-19 virus and is intended to help clinicians understand if their patient had a recent ...

“We continue to see strong momentum in our base business as reflected in our fourth quarter 2020 Core revenue growth of 9%,” said Chris Smith, chairman and chief executive officer, Ortho Clinical ...

RARITAN, N.J., May 3, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced the availability of enhanced ...

RARITAN, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient ...

Ortho Clinical Diagnostics today announced U.S. Food and Drug Administration (FDA) approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 ...

Medical diagnostics firm Quidel Corporation plans to acquire Ortho Clinical Diagnostics, American Association for Clinical Chemistry reported March 1. The deal gives Quidel access to Ortho Clinical ...

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics with a rich history of bringing critical tests for infectious diseases to market, today announced it is working with Quest ...

Ortho Clinical Diagnostics Holdings plc, an in-vitro diagnostics company, has raised $1.3 billion for its IPO after pricing its 76 million shares at $17 per share. The stock began trading January 28, ...

Ortho Clinical Diagnostics is hoping to pay down a large portion of its debts by riding a wave of COVID-19 and broader in vitro lab testing demands to a $1.5 billion IPO. The company is offering 70 ...